Biomarkers of Drug-Induced Cellular Proteostasis Disruption: A Comprehensive Clinical Review

Abstract

Drug-induced disruption of cellular proteostasis is a significant mechanism underpinning adverse drug reactions, particularly in organs with high protein turnover such as the liver, kidney, and nervous system. This review synthesizes recent evidence on biomarkers that signal drug-induced proteostasis disturbances, providing clinicians and researchers with an up-to-date resource for the detection, monitoring, and management of toxicities related to impaired protein homeostasis. We discuss mechanistic underpinnings, epidemiological insights, diagnostic approaches, and guideline-based recommendations with a focus on clinical translation.

Introduction

Proteostasis, the maintenance of cellular protein homeostasis, is crucial for cell function and survival. Many pharmacological agents, particularly those used in oncology, neurology, and infectious disease, can disrupt proteostasis by interfering with protein synthesis, folding, trafficking, or degradation. The resulting accumulation of misfolded or aggregated proteins leads to cellular stress, organelle dysfunction, and potentially cell death. Given the expanding therapeutic armamentarium and increasing polypharmacy, drug-induced proteostasis disruption is an emerging concern in clinical practice, necessitating robust biomarkers for early detection and intervention.

Epidemiology / Disease Burden

The true prevalence of drug-induced proteostasis disruption is likely underestimated due to limited biomarker availability and nonspecific clinical presentations. Epidemiological data suggest that proteotoxicity contributes significantly to adverse drug reactions, especially in patients receiving proteasome inhibitors, immunomodulatory agents, antibiotics, and certain antiviral therapies. Organ-specific burdens are notable in hepatotoxicity (e.g., acetaminophen, anti-tubercular drugs), nephrotoxicity (e.g., aminoglycosides, cisplatin), and neurotoxicity (e.g., bortezomib, antiretrovirals). Hospital-based studies estimate that up to 20% of severe drug-induced organ injuries may involve proteostasis disruption mechanisms.

Pathophysiology

Drugs may perturb proteostasis by direct inhibition of molecular chaperones, impairment of the ubiquitin-proteasome system, lysosomal dysfunction, or induction of endoplasmic reticulum (ER) stress. For example, proteasome inhibitors used in multiple myeloma block protein degradation, leading to unfolded protein accumulation and apoptosis. Aminoglycosides interfere with protein translation, producing misfolded polypeptides and triggering ER stress. The resulting activation of the unfolded protein response (UPR) can initially be adaptive but may lead to apoptosis if the stress is unresolved. Oxidative stress, mitochondrial dysfunction, and inflammatory signaling often amplify the injury cascade.

Risk Factors

Risk of drug-induced proteostasis disruption is heightened in patients with underlying genetic mutations affecting proteostasis networks (e.g., cystic fibrosis, alpha-1 antitrypsin deficiency), advanced age, polypharmacy, pre-existing organ dysfunction, and those receiving high-dose or prolonged drug regimens. Concomitant exposures to environmental toxins or metabolic stressors can further exacerbate susceptibility. Pharmacogenomic variability in drug metabolism and proteostasis pathways also modulates individual risk profiles.

Clinical Features

Clinical manifestations of proteostasis disruption are often organ-specific and may be nonspecific, including fatigue, jaundice, encephalopathy, nephrotic syndrome, or neuropathy. Laboratory findings may reveal elevated transaminases, creatinine, or proteinuria. In severe cases, multi-organ dysfunction can occur. The presence of concurrent cytopenias or immune dysregulation may suggest a broader impact on cellular health. Delineation of proteostasis-related toxicity from other drug-induced injuries may be challenging without specific biomarkers.

Diagnosis

Diagnosis relies on a combination of clinical suspicion, temporal association with drug exposure, exclusion of alternative causes, and, increasingly, biomarker assessment. Emerging biomarkers include circulating heat shock proteins (HSP70, HSP90), protein aggregates (e.g., ubiquitinated proteins, p62/SQSTM1), markers of ER stress (GRP78/BiP, CHOP), and proteasome activity assays. Proteomic profiling and next-generation sequencing are being explored to identify novel markers. Noninvasive imaging modalities such as PET tracers for protein aggregates are in early clinical evaluation.

Treatment & Management

Primary management involves prompt discontinuation or dose reduction of the offending agent. Supportive care is tailored to organ involvement, including hepatoprotective strategies, renal replacement therapy, or neuroprotective agents. Pharmacological chaperones, chemical proteostasis modulators, and antioxidants are under investigation for their therapeutic potential in mitigating proteotoxicity. Early detection via biomarkers can facilitate timely intervention and prevent irreversible tissue damage.

Recent Advances / Emerging Therapies

Recent research has identified several promising biomarker candidates, such as exosomal HSPs, microRNAs regulating proteostasis (miR-211, miR-34a), and post-translational modifications of key proteostasis regulators. Mass spectrometry-based proteomics is enhancing sensitivity and specificity of detection. Novel therapeutics targeting UPR modulation, autophagy enhancement, and selective proteasome inhibition are in preclinical and early-phase clinical trials. Integration of multi-omics data holds promise for personalized risk assessment and precision therapeutics.

Guideline Recommendations

Current clinical guidelines emphasize careful monitoring of at-risk patients, baseline and periodic assessment of organ function, and vigilance for early signs of toxicity. The use of validated biomarkers is recommended where available, particularly in high-risk populations or with known proteotoxic drugs. Multidisciplinary collaboration between pharmacologists, pathologists, and clinicians is advocated to optimize diagnosis and management. Guidelines are evolving as novel biomarkers and therapies are validated in larger patient cohorts.

Conclusion

Drug-induced disruption of cellular proteostasis is an under-recognized yet clinically significant contributor to adverse drug reactions. Advances in biomarker discovery are improving our ability to detect and manage these toxicities early, with important implications for patient safety and therapeutic efficacy. Ongoing research and interdisciplinary collaboration are essential to translate mechanistic insights into routine clinical practice, ultimately enhancing outcomes for patients exposed to proteostasis-disrupting drugs.